# Colorectal and Anal Carcinomas

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/colorectal-and-anal-carcinomas/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the treatment and management of anal cancer, including the use of chemoradiation, intensity-modulated radiation therapy, and chemotherapy. It also explores the impact of HIV infection on treatment outcomes, imaging techniques such as FDG-PET/CT, and the long-term quality of life for survivors. Additionally, it delves into salvage surgery for recurrent or persistent anal cancer. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t13110 |
| Works | 294 |

## Topic papers all

Showing 15 of 294.

- [Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer](https://scholariq.org/papers/preoperative-radiotherapy-combined-with-total-mesorectal-excision-for-resectable-2/)
- [Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial](https://scholariq.org/papers/neoadjuvant-chemoradiotherapy-plus-surgery-versus-surgery-alone-for-oesophageal/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix](https://scholariq.org/papers/concurrent-chemotherapy-and-pelvic-radiation-therapy-compared-with-pelvic/)
- [Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer](https://scholariq.org/papers/durable-clinical-benefit-with-nivolumab-plus-ipilimumab-in-dna-mismatch-repair/)
- [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial](https://scholariq.org/papers/preoperative-radiotherapy-combined-with-total-mesorectal-excision-for-resectable/)
- [Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial](https://scholariq.org/papers/laparoscopic-versus-open-surgery-for-rectal-cancer-color-ii-short-term-outcomes/)
- [Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/short-course-radiotherapy-followed-by-chemotherapy-before-total-mesorectal/)
- [Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/)
- [Definition and grading of anastomotic leakage following anterior resection of the rectum: A proposal by the International Study Group of Rectal Cancer](https://scholariq.org/papers/definition-and-grading-of-anastomotic-leakage-following-anterior-resection-of/)
- [A Randomized Trial of Laparoscopic versus Open Surgery for Rectal Cancer](https://scholariq.org/papers/a-randomized-trial-of-laparoscopic-versus-open-surgery-for-rectal-cancer/)
- [Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer](https://scholariq.org/papers/deep-learning-can-predict-microsatellite-instability-directly-from-histology-in/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy](https://scholariq.org/papers/int-0123-radiation-therapy-oncology-group-94-05-phase-iii-trial-of-combined/)
- [Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-oesophageal-squamous/)

## Topic primary papers

Showing 15 of 24.

- [Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC](https://scholariq.org/papers/neoadjuvant-pd-1-inhibitor-sintilimab-in-nsclc/)
- [Human papillomavirus genotype distribution in anal cancer in France: The EDiTH V study](https://scholariq.org/papers/human-papillomavirus-genotype-distribution-in-anal-cancer-in-france-the-edith-v/)
- [A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma](https://scholariq.org/papers/a-randomized-trial-of-intensive-versus-minimal-surveillance-of-patients-with/)
- [High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease](https://scholariq.org/papers/high-risk-of-anal-and-rectal-cancer-in-patients-with-anal-and-or-perianal-crohn/)
- [HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients](https://scholariq.org/papers/hiv-positive-patients-with-anal-carcinoma-have-poorer-treatment-tolerance-and/)
- [The American Brachytherapy Society consensus statement on intraoperative radiation therapy](https://scholariq.org/papers/the-american-brachytherapy-society-consensus-statement-on-intraoperative/)
- [Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma](https://scholariq.org/papers/efficacy-and-safety-in-analysis-of-short-course-radiation-followed-by-mfolfox-6/)
- [Leukocytosis and neutrophilia predicts outcome in anal cancer](https://scholariq.org/papers/leukocytosis-and-neutrophilia-predicts-outcome-in-anal-cancer/)
- [External validation of leukocytosis and neutrophilia as a prognostic marker in anal carcinoma treated with definitive chemoradiation](https://scholariq.org/papers/external-validation-of-leukocytosis-and-neutrophilia-as-a-prognostic-marker-in/)
- [Transanal Minimally Invasive Surgery (TAMIS): Standardizing a Reproducible Procedure](https://scholariq.org/papers/transanal-minimally-invasive-surgery-tamis-standardizing-a-reproducible/)
- [Mucinous adenocarcinoma arising from chronic perianal fistula—a multidisciplinary approach](https://scholariq.org/papers/mucinous-adenocarcinoma-arising-from-chronic-perianal-fistula-a/)
- [Mucinous Adenocarcinoma Arising in Chronic Perianal Fistula: Good Results with Neoadjuvant Chemoradiotherapy Followed by Surgery](https://scholariq.org/papers/mucinous-adenocarcinoma-arising-in-chronic-perianal-fistula-good-results-with/)
- [Adenocarcinoma del canal anal. Revisión de conjunto](https://scholariq.org/papers/adenocarcinoma-del-canal-anal-revision-de-conjunto/)
- [Adenocarcinoma of the Anal Canal. Narrative Review](https://scholariq.org/papers/adenocarcinoma-of-the-anal-canal-narrative-review/)
- [Fistula-Associated Anal Adenocarcinoma: A 20-Year Single-Center Experience](https://scholariq.org/papers/fistula-associated-anal-adenocarcinoma-a-20-year-single-center-experience/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.